Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Immunovant, Inc.NASDAQ: IMVT

Weighted Avg Shares · Q2 FY2027 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2027 weighted avg shares of 206.67M shares rose 19.0% year over year, behind the +24.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +19.0% toward the trailing-twelve-month pace of +24.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
206.67M+0.5% QoQ
Last fiscal yearMar 2026
182.42M+20.4% YoY
LTMSep 2026
199.36M+24.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.0%——
1 year+20.4%——
3-year CAGR+14.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2026
182.42M USD
Year-over-year change
+20.4%
4-year CAGR
+13.6%

Weighted Avg Shares vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 weighted avg shares of 199.36M shares is the highest of the 11 companies compared; the peer median is 52.82M shares.
  • Its year-over-year change of +24.0% is the 4th highest of 10, against a peer median of +13.7%.
  • Over three fiscal years its annual growth of +14.0% compares with a peer median of +23.4%.
IMVT Competitors Peer median
Weighted Avg Shares for IMVT and competitors
Company Period LTM YoY 3-year CAGR
IMVTImmunovant, Inc.LTM Sep 2026199.36M +24.0%+14.0%
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
TGTXTG Therapeutics, Inc.LTM Sep 2026142.49M -2.4%+2.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
CABACabaletta Bio, Inc.LTM Mar 202694.61M +91.6%+51.6%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+9.3%
ZBIOZenas BioPharma, Inc.LTM Mar 202646.54M +13.7%+5.3%
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
Peer median (excluding IMVT) 52.82M+13.7%+23.4%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.